A novel PAA derivative with enhanced drug efficacy in pancreatic cancer cell lines

Ali Alsuraifi, Paul Kong Thoo Lin, Anthony Curtis, Dimitrios A. Lamprou, Clare Hoskins

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)
4 Downloads (Pure)


Nanoparticles have been shown to be effective drug carriers in cancer therapy. Pancreatic cancer forms dense tumours which are often resistant to drug molecules. In order to overcome such multidrug resistance, new drug entities, novel delivery systems and combination therapy strategies are being explored. In this paper, we report the design and synthesis of a poly(allylamine)-based amphiphile modified with hydrophobic naphthalimido pendant groups. Bisnaphthalimide compounds have been shown to possess anticancer activity.
The potential of this polymer to encapsulate, solubilize and enhance drug (5-fluorouricil and bis-(naphthalimidopropyl)-diaminooctane) cytotoxicity in BxPC-3 cells was evaluated. Our studies showed that the insoluble drugs could be formulated up to 4.3 mg mL−1 and 2.4 mg mL−1 inside the amphiphiles, respectively. Additionally, the novel poly(allylamine)-naphthalimide carrier resulted in an amplification of cytotoxic effect with drug treatment after 24 h, and was capable of reduction of 50% cell population at concentrations as low as 3 µg mL−1
Original languageEnglish
Article number91
Number of pages13
Issue number4
Publication statusPublished - 8 Oct 2018


  • nanomedicine
  • nanopharmaceutics
  • drug solubilisation
  • pancreatic cancer
  • bisnaphthalimide


Dive into the research topics of 'A novel PAA derivative with enhanced drug efficacy in pancreatic cancer cell lines'. Together they form a unique fingerprint.

Cite this